Dyne Therapeutics, Inc.

NasdaqGS DYN

Dyne Therapeutics, Inc. Net Cash Used For Investing Activities for the Trailing 12 Months (TTM) ending September 30, 2024: USD -161.87 M

Dyne Therapeutics, Inc. Net Cash Used For Investing Activities is USD -161.87 M for the Trailing 12 Months (TTM) ending September 30, 2024, a -312.00% change year over year. Net cash used for investing activities is total cash inflows and outflows related to activities intended to generate future income and cash flows from investments.

Dyne Therapeutics, Inc. Net Cash Used For Investing Activities for the Trailing 12 Months (TTM) ending September 30, 2023 was USD 76.35 M, a 12.73% change year over year.
Dyne Therapeutics, Inc. Net Cash Used For Investing Activities for the Trailing 12 Months (TTM) ending September 30, 2022 was USD 67.73 M, a 137.04% change year over year.
Dyne Therapeutics, Inc. Net Cash Used For Investing Activities for the Trailing 12 Months (TTM) ending September 30, 2021 was USD -182.88 M, a -15,464.26% change year over year.
Dyne Therapeutics, Inc. Net Cash Used For Investing Activities for the Trailing 12 Months (TTM) ending September 30, 2020 was USD -1.18 M.

Key data

Date	Net Cash Used For Investing Activities	Net Cash Used Provided By Financing Activities	Dividends Paid	Capital Expenditure

NasdaqGS: DYN

Dyne Therapeutics, Inc.

CEO	Mr. John G. Cox M.B.A.
IPO Date	Sept. 17, 2020
Location	United States
Headquarters	1560 Trapelo Road
Employees	173
Sector	Health Care
Industries Biotechnology Pharmaceuticals

Description

Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was incorporated in 2017 and is headquartered in Waltham, Massachusetts..

Key trends

Past 5 years